STOCK TITAN

Context Therapeutics Inc - CNTX STOCK NEWS

Welcome to our dedicated news page for Context Therapeutics (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Context Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Context Therapeutics's position in the market.

Rhea-AI Summary
Context Therapeutics Inc. announced the submission of an Investigational New Drug (IND) application for CTIM-76 to the FDA, marking a crucial step towards a Phase 1 clinical trial for CLDN6-positive gynecologic and testicular cancers. The CEO highlighted the program's potential and the team's dedication to advancing the therapy swiftly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. announced financial results for 2023, with cash reserves of $14.4 million. The company plans to file an IND for CTIM-76 by March 2024, targeting CLDN6-positive tumors. Recent highlights include amending collaboration terms with Integral Molecular, presenting promising preclinical data, and upcoming participation in the Needham Virtual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. (CNTX) announces Q3 2023 financial results, with $21.7 million in cash and cash equivalents. The company is on track to file an IND for CTIM-76 in late Q1 2024, supported by promising preclinical data presented at the SITC 38th Annual Meeting. CTIM-76 demonstrated broad therapeutic potential and differentiated product profile, positioning it as a strong candidate for addressing CLDN6-positive tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
Rhea-AI Summary
Context Therapeutics Inc. announces encouraging preclinical data for CTIM-76, a Claudin 6 x CD3 T-cell engaging bispecific antibody. CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models. Benchmarking studies show CTIM-76's differentiated product profile. CTIM-76 IND filing on track for late Q1 2024. Data to be presented at SITC 38th Annual Meeting on November 3rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. will present a poster on its preclinical asset, CTIM-76, at the SITC 38th Annual Meeting. The poster will discuss the development of CTIM-76, a highly specific Claudin 6 bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
none
-
Rhea-AI Summary
Context Therapeutics Inc. announces financial results for Q2 2023 and provides updates on preclinical asset CTIM-76
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
conferences
Context Therapeutics Inc

Nasdaq:CNTX

CNTX Rankings

CNTX Stock Data

23.79M
13.89M
6.86%
30.06%
0.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Philadelphia

About CNTX

context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.